Memo Therapeutics is a technology company.
Memo Therapeutics has raised $75.0M across 3 funding rounds.
Memo Therapeutics has raised $75.0M in total across 3 funding rounds.
Memo Therapeutics has raised $75.0M in total across 3 funding rounds.
Memo Therapeutics's investors include Kurma Partners, Adjuvant Capital, Pureos Bioventures.
Memo Therapeutics AG (MTx) is a late-stage Swiss biotech company developing best-in-class therapeutic antibodies targeting viral infections in transplant patients and novel oncology indications.[1][2][3] Its lead product, potravitug, is a highly potent monoclonal antibody in Phase II trials for BK polyomavirus (BKPyV) viremia in kidney transplant recipients, addressing a condition that doubles kidney loss risk and triples mortality with no approved treatments available.[1][2][3] The company serves transplant patients and cancer sufferers, leveraging its proprietary DROPZYLLA® platform to translate human immune responses into superior medicines, with partnerships including Ono Pharmaceutical and universities like ETH Zurich.[1][3]
MTx demonstrates strong growth momentum, having completed patient recruitment in the largest-ever placebo-controlled Phase II trial (SAFE KIDNEY II, NCT05769582) for potravitug, involving 90 U.S. patients to assess safety, tolerability, and efficacy.[2] Additional programs target cytomegalovirus (CMV) infections (preclinical) and oncology via DROPZYLLA®, positioning MTx for potential first-in-class therapies in unmet needs.[3][5]
Founded in Switzerland, Memo Therapeutics pioneered antibody discovery through immune repertoire analysis, evolving from early platform development to late-stage clinical assets.[3][4] Key figures include co-founder and CSO Christoph Esslinger, PhD, alongside CEO Erik van den Berg, CMO Jürgen Beck, MD, and CDOs Gerald Parzmair, PhD, and Frits van Alphen, MD; the board features independent chairperson Paul Carter and non-executives from partners like Ysios Capital.[1]
The idea emerged from exploiting microfluidic single-cell cloning to capture full B-cell repertoires across species, enabling rapid screening of millions of antibodies for functional properties—initially via platforms like MemoMAB and DROPZYLLA®.[4][5] Pivotal early traction came from validating potravitug as the most potent anti-BKPyV antibody in trials, fueled by collaborations with University Hospitals of Zurich and Bern, and oncology work with University of Basel and ETH Zurich.[1] A 2025 study published in *Frontiers in Pharmacology* highlighted potravitug's transcytosis across kidney barriers, underscoring clinical progress.[6]
Memo Therapeutics rides the wave of precision biologics in transplant immunology and immuno-oncology, where antibody therapies address rising transplant volumes (e.g., kidney transplants) amid antiviral resistance and BKPyV's 10-30% incidence without treatments.[2][3] Timing aligns with post-pandemic emphasis on viral threats in immunocompromised populations and AI-enhanced discovery platforms like DROPZYLLA®, accelerating from repertoire mining to clinic.[3][4]
Market forces favor MTx: growing biologics market (projected >$500B by 2030), unmet needs in transplant virology (BKPyV linked to graft loss), and Switzerland's biotech hub status enabling talent and funding.[1][3] It influences the ecosystem by partnering platforms for antigen discovery, advancing Swiss innovation in global healthcare, and validating human immune-derived antibodies over synthetic designs.[1][3]
Memo Therapeutics is poised for Phase II potravitug readout from SAFE KIDNEY II, potentially yielding the first approved BKPyV therapy and catalyzing partnerships or acquisition in transplant antivirals.[2] Oncology pipeline expansion via DROPZYLLA® could yield INDs by 2027, riding trends in repertoire-based discovery and combination immunotherapies amid rising cancer incidence.[1][3]
Evolving influence may see MTx as a platform leader, licensing tech to big pharma while advancing assets; success hinges on trial data and funding in a high-interest biologics market, ultimately transforming outcomes for vulnerable patients as in its mission.[1][2]
Memo Therapeutics has raised $75.0M across 3 funding rounds. Most recently, it raised $22.0M Series C in May 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2024 | $22.0M Series C | Kurma Partners | |
| Nov 1, 2023 | $28.0M Series C | Adjuvant Capital, Kurma Partners, Pureos Bioventures | |
| Feb 1, 2022 | $25.0M Series B | Adjuvant Capital, Kurma Partners, Pureos Bioventures |